Back to Journals » Vascular Health and Risk Management » Volume 9

The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report

Authors Ferrario CM, Joyner J, Colby C, Exuzides A, Moore M, Simmons D, Bestermann Jr W, Frech-Tamas F

Received 8 March 2013

Accepted for publication 14 June 2013

Published 22 July 2013 Volume 2013:9 Pages 391—400

DOI https://doi.org/10.2147/VHRM.S44950

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Carlos M Ferrario,1 JaNae Joyner,2 Chris Colby,3 Alex Exuzides,3 Michael Moore,2,6 Debra Simmons,2 William Bestermann Jr,4 Feride Frech-Tamas5

1Department of Surgery, Internal Medicine–Nephrology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; 2Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; 3ICON Late Phase and Outcomes Research, San Francisco, CA, USA; 4Vascular Medicine Center, Holston Medical Group, Kingsport, TN, USA; 5Department of Health Economics, Daiichi Sankyo, Inc, Parsippany, NJ, USA; 6Danville Regional Medical Center, Danville, VA, USA

Abstract: The Global Vascular Risk Management (GVRM) Study is a 5-year prospective observational study of 87,863 patients (61% females) with hypertension and associated cardiovascular risk factors began January 1, 2010. Data are gathered electronically and cardiovascular risk is evaluated using the Consortium for Southeastern Hypertension Control™ (COSEHC™)-11 risk score. Here, we report the results obtained at the completion of 33 months since study initiation. De-identified electronic medical records of enrolled patients were used to compare clinical indicators, antihypertensive medication usage, and COSEHC™ risk scores across sex and diabetic status subgroups. The results from each subgroup, assessed at baseline and at regular follow-up periods, are reported since the project initiation. Inference testing was performed to look for statistically significant differences between goal attainments rates between sexes. At-goal rates for systolic blood pressure (SBP) were improved during the 33 months of the study, with females achieving higher goal rates when compared to males. On the other hand, at-goal control rates for total and low-density lipoprotein (LDL) cholesterol (chol) were better in males compared to females. Diabetic patients had lower at-goal rates for SBP and triglycerides but higher rates for LDL-chol. The LDL-chol at-goal rates were higher for males, while high-density lipoprotein (HDL)-chol rates were higher for females. Utilization of antihypertensive medications was similar during and after the baseline period for both men and women. Patients taking two or more antihypertensive medications had higher mean COSEHC™-11 scores compared to those on monotherapy. With treatment, hypertensive patients can reach SBP and cholesterol goals; however, population-wide improvement in treatment goal adherence continues to be a challenge for physicians. The COSEHC™ GVRM Study shows, however, that continuous monitoring and feedback to physicians of accurate longitudinal data is an effective tool in achieving better control rates of cardiovascular risk factors.

Keywords: cardiovascular risk, coronary heart disease, dyslipidemia, electronic medical records, hypertension, metabolic syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Using portable negative pressure wound therapy devices in the home care setting

Burke JR, Morley R, Khanbhai M

Smart Homecare Technology and TeleHealth 2014, 2:129-135

Published Date: 9 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014